DOP2024000232A - Composiciones farmacéuticas de glp1 - Google Patents
Composiciones farmacéuticas de glp1Info
- Publication number
- DOP2024000232A DOP2024000232A DO2024000232A DO2024000232A DOP2024000232A DO P2024000232 A DOP2024000232 A DO P2024000232A DO 2024000232 A DO2024000232 A DO 2024000232A DO 2024000232 A DO2024000232 A DO 2024000232A DO P2024000232 A DOP2024000232 A DO P2024000232A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- glp1
- pharmaceutical compositions
- fluoro
- oxoimi
- dimethyloxan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 | |
| PCT/US2023/021637 WO2023220109A1 (en) | 2022-05-11 | 2023-05-10 | Glp1 pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000232A true DOP2024000232A (es) | 2024-12-30 |
Family
ID=86732348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000232A DOP2024000232A (es) | 2022-05-11 | 2024-11-11 | Composiciones farmacéuticas de glp1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250302809A1 (enExample) |
| EP (1) | EP4522129A1 (enExample) |
| JP (1) | JP7767651B2 (enExample) |
| KR (1) | KR20250002778A (enExample) |
| CN (1) | CN119173255A (enExample) |
| AR (1) | AR129296A1 (enExample) |
| AU (1) | AU2023269995A1 (enExample) |
| CA (1) | CA3253043A1 (enExample) |
| CL (1) | CL2024003392A1 (enExample) |
| CO (1) | CO2024015285A2 (enExample) |
| DO (1) | DOP2024000232A (enExample) |
| IL (1) | IL316629A (enExample) |
| MX (1) | MX2024013839A (enExample) |
| PE (1) | PE20251285A1 (enExample) |
| TW (2) | TWI867526B (enExample) |
| WO (1) | WO2023220109A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| WO2025108361A1 (zh) * | 2023-11-21 | 2025-05-30 | 江苏恒瑞医药股份有限公司 | 杂环类化合物、其制备方法及其在医药上的应用 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| MXPA03006404A (es) * | 2001-01-18 | 2004-12-02 | Upjohn Co | Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada. |
| CA2662748A1 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| EP3984523B1 (en) * | 2018-12-07 | 2025-09-03 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| UY38696A (es) * | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
| SMT202500315T1 (it) * | 2020-09-09 | 2025-11-10 | Crinetics Pharmaceuticals Inc | Formulazioni di un modulatore della somatostatina |
| KR20250002779A (ko) * | 2022-05-11 | 2025-01-07 | 일라이 릴리 앤드 캄파니 | Glp1 정제 조성물 |
-
2023
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
-
2024
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250302809A1 (en) | 2025-10-02 |
| TW202410894A (zh) | 2024-03-16 |
| CA3253043A1 (en) | 2023-11-16 |
| CN119173255A (zh) | 2024-12-20 |
| MX2024013839A (es) | 2024-12-06 |
| WO2023220109A1 (en) | 2023-11-16 |
| KR20250002778A (ko) | 2025-01-07 |
| AU2023269995A1 (en) | 2024-11-14 |
| IL316629A (en) | 2024-12-01 |
| PE20251285A1 (es) | 2025-05-14 |
| CO2024015285A2 (es) | 2024-11-28 |
| JP7767651B2 (ja) | 2025-11-11 |
| CL2024003392A1 (es) | 2025-03-14 |
| TW202508581A (zh) | 2025-03-01 |
| AR129296A1 (es) | 2024-08-07 |
| JP2025515706A (ja) | 2025-05-20 |
| EP4522129A1 (en) | 2025-03-19 |
| TWI867526B (zh) | 2024-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2024000232A (es) | Composiciones farmacéuticas de glp1 | |
| Ellepola et al. | Oral candidal infections and antimycotics | |
| DOP2024000235A (es) | Composiciones de comprimidos de glp1 | |
| MA27729A1 (fr) | Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre | |
| MA30807B1 (fr) | Compositions pharmaceutiques. | |
| EE05103B1 (et) | Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid | |
| MX9706449A (es) | Composicion farmaceutica para compuestos de piperidinalcanol. | |
| GEP20247638B (en) | Pharmaceutical combination of prmt5 inhibitors | |
| ECSP024352A (es) | Nueva composicion farmaceutica | |
| MA52424B1 (fr) | Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide | |
| ES2181055T3 (es) | Formulaciones galenicas que contienen antagonistas de opiaceos. | |
| PE20121820A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella | |
| ECSP045104A (es) | Ligandos de los receptores de los cannabinoides | |
| CY1113462T1 (el) | Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο | |
| PE20071029A1 (es) | Compuestos de cinamida no peptidicos biciclicos como inhibidores de beta amiloides | |
| Elguezabal et al. | Inhibition of adherence of Candida albicans and Candida dubliniensis to a resin composite restorative dental material by salivary secretory IgA and monoclonal antibodies | |
| MA42946B1 (fr) | Sels et formes solides d'un antibiotique de type monobactame | |
| MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| AR058085A1 (es) | Sal de dihidrogeno fosfato de un antagonista del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| NZ776354A (en) | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | |
| DE69518237D1 (de) | Feste pharmazeutische zubereitung mit (s)-2-(4-isobutylphenyl)propionsäure als wirkstoff und mikrokristalliner cellulose und kolloidalem silica als hilfstoff | |
| MA30691B1 (fr) | Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium. | |
| MA26788A1 (fr) | COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION | |
| EA200601015A1 (ru) | Пероральные композиции дезоксипеганина и их применение | |
| WO2022115681A3 (en) | Methods and compositions for oral pilocarpine liquid |